Clinical Trials Logo

Constipation clinical trials

View clinical trials related to Constipation.

Filter by:

NCT ID: NCT02867917 Completed - Constipation Clinical Trials

Comparison of Taste and Palatability in Fiber Supplements

Start date: November 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to compare 1. taste and 2. texture/palatability of Metamucil orange®, Volcolon® and generic orange psyllium.

NCT ID: NCT02863848 Completed - Constipation Clinical Trials

Effect of Inulin-type Fructans on Constipated Children.

CONSTICHILD
Start date: September 2012
Phase: N/A
Study type: Interventional

The main objective of this Pilot study was to assess the beneficial effects of a daily supplementation with Orafti inulin‐type fructans in 2‐5 year old constipated children The study is primary aimed to develop a feasibility study to assess the beneficial effect of inulin‐type fructans in the described population with regard to the adequate criteria for a larger trial. Secondary objectives are to obtain data about the feasibility of the protocol (as pilot study). To obtain data useful to perform sample size calculations for a big study designed specifically to investigate the beneficial effect of inulin‐type fructans in the treatment of constipated children. Study design and subjects: Double‐blind, randomized, placebo‐controlled parallel group trial; where 2‐5 year‐old constipated children received inulin‐type fructans or the same amount of placebo (maltodextrin) during 6 weeks. The study protocol was approved by the local Ethical Committees. Outcomes: primary outcome was stool consistency. Secondary outcomes were: stool frequency, gastrointestinal symptoms (abdominal pain and pain during defecation), additional medication required (yes/no), and colonic transit time. Stool samples at baseline, end of intervention and after follow‐up were obtained in order to be analysed to know about the microbiota. Dietary intake was also recorded at baseline, end of intervention and after follow-up. Principal subject inclusion criteria: Subjects were recruited if fulfil the Rome III constipation criteria (Mainly hard stools plus stool retention, or pain, or low frequency). Principal subject exclusion criteria: Age under 2 or over 5 years, diapers use, use of laxative during the study and 2 weeks before, use of pre‐ probiotics or antibiotics during the study and 4 weeks before, organic causes of defecation disorders, other metabolic or renal abnormalities or mental retardation, no parent's command of any local language.

NCT ID: NCT02854098 Recruiting - Clinical trials for Functional Constipation

The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children

MobCon
Start date: April 2015
Phase: N/A
Study type: Observational [Patient Registry]

Benign Hypermobility Joint Syndrome is a group of inherited abnormalities in the structure of connective tissues, manifested by disturbances in the proportion of collagen. The main symptoms of this syndrome include: laxity of joint capsules and ligaments, hypermobility of the joints, as well as numerous disturbances in the functioning of internal organs that contain connective tissue, including the gastrointestinal tract. Hypermobility of joints affects approximately 10% of the population of Western countries, is more common in small children and female. Modified Beighton scale is the basic scale for assessing hypermobility of joints. The scale (as assessed using the goniometer) is a reliable tool for the evaluation of excessive laxity of the connective tissue in children. Functional constipation is a very common condition, affecting approximately 3-5% of children and adolescents, with peak onset between 2 and 4 years of age. The etiology of this disorder is multifactorial, and till day it is still exactly unknown why some children develop constipation, while in others we can observe the correct scheme of defecation. Suspending stool enhances the retention of fecal masses, which subsequently causes painful defecation. Diagnosis is based on history, clinical symptoms and physical examination. Increased susceptibility of the wall of the distal gastrointestinal tract could explain the predisposition of some children to retain fecal masses and the development of constipation. Due to the unclear etiology of functional constipation, it seems reasonable to conduct a study assessing whether excessive laxity of connective tissue (assessed on the basis of the hypermobility of the joints) facilitates the accumulation of stool in the large intestine, and so is the one of the reasons leading to development of functional constipation in children.

NCT ID: NCT02844426 Completed - Clinical trials for Slow Transit Constipation

Effect of a Synbiotic on Symptoms of Patients With STC

Start date: September 2015
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of synbiotic (BIFICOPEC) containing Enterococci, Bifidobacteria, Lactobacilli triple viable bacteria and pectin in patients with slow transit constipation.

NCT ID: NCT02842411 Recruiting - Constipation Clinical Trials

Risk Factors for Inadequate Bowel Preparation in Patients With Chronic Constipation

Start date: August 2016
Phase: N/A
Study type: Observational

Chronic constipation is one of the risk factors of inadequate bowel preparation, which could influence the effect of colonoscopy. The risk factors associated with inadequate bowel preparation in constipated patients remains unclear. Here the investigators investigated the high risk factors which might have influence on bowel preparation quality in a prospective cohort of patients with functional constipation.

NCT ID: NCT02839889 Terminated - Pain Clinical Trials

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

Start date: September 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if naloxegol can be used in the treatment of opioid-induced constipation in patients with cancer and pain. This phase 4 study consists of a two week randomized double blind period followed by a two week open-label period.

NCT ID: NCT02838797 Completed - Parkinson's Disease Clinical Trials

RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease

RQ-10
Start date: June 2016
Phase: Phase 1
Study type: Interventional

This is a study to determine the safety and tolerability of a new medicine (RQ10) for gastrointestinal symptoms in Parkinson's disease. The investigators will also begin to look at the effect of this medicine on gastrointestinal problems. The results will determine if future studies are appropriate. In this study, RQ10 will be compared to a placebo (a look-alike inactive substance). Participation will include multiple office visits. Approximately 48 people will participate.

NCT ID: NCT02837783 Terminated - Clinical trials for Irritable Bowel Syndrome Characterized by Constipation

A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)

Start date: December 21, 2016
Phase: Phase 4
Study type: Interventional

The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.

NCT ID: NCT02836717 Completed - Constipation Clinical Trials

Long Term Efficacy of Sacral Nerve Modulation (SNM) in Patients With Constipation or Stool Incontinence

Start date: April 2016
Phase:
Study type: Observational

The aim of this study is to determine the success rate, the success duration, the complication rate, maintenance effort and quality of life several years after sacral nerve modulation (SNM) treatment for constipation or stool incontinence.

NCT ID: NCT02829047 Terminated - Constipation Clinical Trials

Tolerability, Safety and Efficacy of a New Frequency of Vibrant Capsule Administration

Start date: August 2016
Phase: N/A
Study type: Interventional

The study is a prospective, multicenter, open-label, single-arm study, to evaluate the tolerability, safety and efficacy of the Vibrant Capsule in relieving constipation.